In Europe and North America, patient engagement in drug development is now expected, though not perfect. In this session, a panel of patient, industry, and regulator stakeholders will discuss the thinking and initiatives in other global regions to give patients a voice. We will look beyond Europe and North America to explore the thinking and efforts in other regions to engage patients in the medical product lifecycle. What efforts are underway or emerging to give patients a voice? What cultural, societal, and economic factors drive current thoughts and practices? Who are the influencers who are encouraging change? A diverse panel representing patient groups, regulators and industry from regions such as Asia and Latin America will talk about current experience, hopes, and aspirations for patient engagement worldwide.
Learning Objective : Describe current practices for patient engagement in drug development and regulation in regions such as Asia and Latin America; Compare/contrast perspectives of patient, industry, and regulator stakeholders within these regions; Discuss cultural, societal, and other factors playing a role in views, practices, and emerging trends on patient engagement in these regions.
Rachel Yang, MD, PhD
Director, International Affairs
Chinese Center For Rare Disorders (CORD), China
Junko Sato, PhD
Office Director, Office of International Cooperation
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Head of Clinical Development Center
Daewoong Pharmaceuticals, Korea, Republic of
Julie Louise Gerberding, MD, MPH
Executive Vice President and Chief Patient Officer
Merck & Co., Inc., United States